The Relative Strength (RS) Rating for Mirum Pharmaceuticals climbed into a new percentile Wednesday, with a rise from 80 to 86.
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks matches up against that of all other stocks.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they begin their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
While Mirum Pharmaceuticals is not near a proper buy zone right now, see if it manages to form and break out from a proper consolidation.
Mirum Pharmaceuticals showed 0% EPS growth in its most recent report, while sales growth came in at 89%.
Mirum Pharmaceuticals earns the No. 23 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
